Evommune ends development of lead asset in chronic hives after mid-stage efficacy woes
BioSpace
With the failure in chronic spontaneous urticaria, Evommune's story is now centered on its anti-IL-18 therapy EVO301, Oppenheimer said, which in February elicited a 33% placebo-adjusted improvement in
pharminent
June 30, 2026 (Last updated: June 30, 2026)
BioSpace
With the failure in chronic spontaneous urticaria, Evommune’s story is now centered on its anti-IL-18 therapy EVO301, Oppenheimer said, which in February elicited a 33% placebo-adjusted improvement in
